Clinical Trials Logo

Adriamycin Toxicity clinical trials

View clinical trials related to Adriamycin Toxicity.

Filter by:
  • None
  • Page 1

NCT ID: NCT03576521 Completed - Breast Cancer Clinical Trials

Evaluation of Ocoxin®-Viusid® in Breast Cancer

Start date: May 13, 2015
Phase: Phase 2
Study type: Interventional

The purpose is to determine the efficacy of the nutritional supplement Ocoxin-Viusid oral solution (OV) in the reduction of acute toxicity of Chemotherapy (CT) treatment with patients with breast carcinoma. A randomized, double-blind phase II clinical trial was designed, with a sample of 120 patients distributed in 2 arms: 60 patients will receive the CT treatment plus the OV, 60 will receive CT plus OV placebo. The OV / placebo will be administered before, during and 3 weeks after the conclusion of the CT. A better tolerance to the treatment is expected with the addition of the nutritional supplement.

NCT ID: NCT03027063 Completed - Clinical trials for Breast Cancer Female

Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.

Start date: January 2017
Phase: N/A
Study type: Interventional

This research is being done to determine whether exercise while receiving doxorubicin or Adriamycin chemotherapy for breast cancer can reduce the cardio-toxic effects of this treatment on the heart and improve other outcomes related to cancer such as tumor markers, nausea, fatigue and the ability to tolerate chemotherapy.